STOCK TITAN

ATM stock plan lifted to $8.84M for CING (NASDAQ: CING) investors

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
424B5

Rhea-AI Filing Summary

The company with Nasdaq symbol CING filed a prospectus supplement that permits at-the-market sales of its common stock with an aggregate offering price of up to $8,840,000 through H.C. Wainwright & Co. under an existing sales agreement. This updates the capacity available under Form S-3 General Instruction I.B.6 and follows earlier sales of common stock with an aggregate sales price of $15,145,503.74 under the prior prospectus.

As of January 12, 2026, the public float was $37,286,229.76, based on 7,339,809 shares held by non-affiliates at a price of $5.08 per share, while the last reported sale price on the Nasdaq Capital Market was $4.87 per share. Over the 12 months up to this supplement, the company sold securities with an aggregate market value of $3,588,312.46 under the same Form S-3 instruction.

Positive

  • None.

Negative

  • None.

 

PROSPECTUS SUPPLEMENT

(To Prospectus dated January 13, 2023)

 

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-269104

 

 

Up to $8,840,000

 

Common Stock

 

This prospectus supplement amends and supplements the information in the prospectus, dated January 13, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-269104), as supplemented by our prospectus supplements dated January 13, 2023, May 5, 2023, March 18, 2024, August 19, 2024, September 3, 2024 and October 15, 2024, or the Prior Prospectus. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

 

We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, or the sales agreement, between H.C. Wainwright & Co., LLC, or Wainwright, acting as the agent, and us.

 

We are filing this prospectus supplement to amend the Prior Prospectus to update the amount of shares we are eligible to sell under General Instruction I.B.6. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $8,840,000 from time to time through Wainwright, which does not include the shares of common stock having an aggregate sales price of $15,145,503.74 that were sold pursuant to the Prior Prospectus to date.

 

As of January 12, 2026, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was $37,286,229.76, which was calculated based on 7,339,809 shares of our outstanding common stock held by non-affiliates at a price of $5.08 per share, the closing price of our common stock on January 8, 2026. During the 12 calendar months prior to, and including, the date of this prospectus, we sold securities with an aggregate market value of $3,588,312.46 pursuant to General Instruction I.B.6. of Form S-3.

 

Our common stock is listed on the Nasdaq Capital Market under the symbol “CING.” On January 12, 2026, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.87 per share.

 

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

H.C. Wainwright & Co.

 

The date of this prospectus supplement is January 12, 2026

 

 

 

FAQ

What is the new at-the-market capacity for CING common stock?

The supplement states that the company may offer and sell shares of its common stock having an aggregate offering price of up to $8,840,000 from time to time through H.C. Wainwright & Co. under the at-the-market program.

How much stock has already been sold under the prior CING prospectus?

The document notes that shares of common stock with an aggregate sales price of $15,145,503.74 were sold pursuant to the prior prospectus before this supplement.

What is CING’s public float as referenced in this supplement?

As of January 12, 2026, the aggregate market value of outstanding common stock held by non-affiliates, or public float, was $37,286,229.76, based on 7,339,809 shares at $5.08 per share.

What recent market prices for CING common stock are disclosed?

The public float calculation used a price of $5.08 per share, the closing price on January 8, 2026, and the last reported sale price on January 12, 2026, was $4.87 per share on the Nasdaq Capital Market.

How much has CING sold under Form S-3 General Instruction I.B.6 in the past year?

The company reports that during the 12 calendar months prior to and including the date of this prospectus, it sold securities with an aggregate market value of $3,588,312.46 pursuant to General Instruction I.B.6 of Form S-3.

Which firm acts as sales agent for CING’s at-the-market offering?

H.C. Wainwright & Co., LLC is identified as the agent under the at-the-market offering agreement through which the company may sell its common stock.

Cingulate Inc

NASDAQ:CING

CING Rankings

CING Latest News

CING Latest SEC Filings

CING Stock Data

40.51M
7.34M
1.81%
5.27%
4.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY